ERBB2 and neoplasm: The approval of trastuzumab deruxtecan(T-DXd) in a tumor-agnostic fashion for HER-2-positive (IHC 3+) tumors has further expanded the clinical scope of HER-2-targeted therapy, providing new opportunities for patients with otherwise limited treatment options.